ALNY Downgraded by Bernstein -- Price Target Lowered to $199
ALNY Downgraded by Bernstein -- Price Target Lowered to $199 GuruFocus
Covered in this story
What has happened since
- Alnylam Pharmaceuticals is up 0.0% since this was published, 2 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Bernstein’s $199 target on $ALNY is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Bernstein’s track record →Analyst targets on Alnylam Pharmaceuticals
- Freedom Broker: $174 → $350 by Oct 2027 · Buy via Investing.com
- RBC Capital Markets: $165 → $280 by Oct 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ALNY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alnylam Pharmaceuticals →Dalsna Finance is currently tracking 48 stories mentioning Alnylam Pharmaceuticals, the earliest published 10 Jul 2026.
Summary aggregated from GuruFocus's public RSS feed. The full reporting belongs to GuruFocus — please read it on their site.